ATE396736T1 - High-density -lipoprotein zur behandlung von schlaganfällen und ischämiezuständen - Google Patents

High-density -lipoprotein zur behandlung von schlaganfällen und ischämiezuständen

Info

Publication number
ATE396736T1
ATE396736T1 AT02774525T AT02774525T ATE396736T1 AT E396736 T1 ATE396736 T1 AT E396736T1 AT 02774525 T AT02774525 T AT 02774525T AT 02774525 T AT02774525 T AT 02774525T AT E396736 T1 ATE396736 T1 AT E396736T1
Authority
AT
Austria
Prior art keywords
stroke
treatment
density lipoprotein
ischemia conditions
ischemia
Prior art date
Application number
AT02774525T
Other languages
English (en)
Inventor
Alphonse Hubsch
Markus Lang
Peter Lerch
Roberto Paterno
Original Assignee
Zlb Bioplasma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP01120026A external-priority patent/EP1285662A1/de
Application filed by Zlb Bioplasma Ag filed Critical Zlb Bioplasma Ag
Application granted granted Critical
Publication of ATE396736T1 publication Critical patent/ATE396736T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Materials For Medical Uses (AREA)
  • Peptides Or Proteins (AREA)
AT02774525T 2001-08-20 2002-08-20 High-density -lipoprotein zur behandlung von schlaganfällen und ischämiezuständen ATE396736T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31360501P 2001-08-20 2001-08-20
EP01120026A EP1285662A1 (de) 2001-08-20 2001-08-20 Rekonstituiertes High-Density -Lipoprotein zur Behandlung von Schlaganfällen und Ischämiezuständen

Publications (1)

Publication Number Publication Date
ATE396736T1 true ATE396736T1 (de) 2008-06-15

Family

ID=26076691

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02774525T ATE396736T1 (de) 2001-08-20 2002-08-20 High-density -lipoprotein zur behandlung von schlaganfällen und ischämiezuständen

Country Status (10)

Country Link
US (2) US20040266660A1 (de)
EP (1) EP1425031B8 (de)
JP (1) JP4284177B2 (de)
AT (1) ATE396736T1 (de)
AU (1) AU2002340825B2 (de)
CA (1) CA2457840C (de)
DE (1) DE60226881D1 (de)
ES (1) ES2304452T3 (de)
WO (1) WO2003018047A2 (de)
ZA (1) ZA200401360B (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL374126A1 (en) * 2002-05-17 2005-10-03 Esperion Therapeutics, Inc. Methods and copositions for the treatment of ischemic reperfusion
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
WO2007000924A1 (ja) * 2005-06-28 2007-01-04 Osaka University プログラニュリン活性を抑制または促進する物質を含む医薬組成物、およびプログラニュリン活性を抑制または促進する物質のスクリーニング方法
US20070110751A1 (en) * 2005-10-25 2007-05-17 Maclellan Robb Compositions and methods for reducing infarct size
JP5601750B2 (ja) * 2007-03-01 2014-10-08 シーエスエル、リミテッド 糖尿病患者の内皮機能異常の治療
AU2007200908B2 (en) * 2007-03-01 2012-08-16 Csl Limited Treatment of endothelial dysfunction in diabetic patients
CN102802618B (zh) 2009-06-25 2014-06-18 泰特拉有限公司 烟酸和米曲肼的治疗组合
EP2676659A1 (de) 2009-07-16 2013-12-25 INSERM (Institut National de la Santé et de la Recherche Médicale) HDL mit einem Therapeutikum und Verwendung bei der Therapie
WO2011044545A2 (en) 2009-10-09 2011-04-14 Sigalov Alexander B Methods and compositions for targeted imaging
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
US12419839B2 (en) 2009-10-09 2025-09-23 Signablok, Inc. Methods and compositions for targeted delivery of protein fragments
WO2012103163A2 (en) * 2011-01-25 2012-08-02 The Cleveland Clinic Foundation Compositions and methods for treating cancer while preventing or reducing cardiotoxicity and/or cardiomyopathy
DK2673296T3 (en) 2011-02-07 2019-02-18 Cerenis Therapeutics Holding Sa LIPOPROTEIN COMPLEXES AND PREPARATION AND APPLICATIONS THEREOF
KR20140036167A (ko) * 2011-03-25 2014-03-25 더 트러스티스 오브 컬럼비아 유니버시티 인 더 시티 오브 뉴욕 페길화된 인간 hdl 입자 및 그의 제조방법
EP2853259A1 (de) 2013-09-30 2015-04-01 Université Pierre et Marie Curie (Paris 6) Rekonstituierte hochdichte Lipoproteinzusammensetzung und Verwendungen davon
CA2947127A1 (en) 2014-05-02 2015-11-19 Cerenis Therapeutics Holding Sa Hdl therapy markers
WO2019030574A1 (en) 2017-08-10 2019-02-14 Cerenis Therapeutics Holding Cargomers
WO2019030575A1 (en) 2017-08-10 2019-02-14 Cerenis Therapeutics Holding APOMÈRES
WO2021191266A1 (en) 2020-03-25 2021-09-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Aerosolization of hdl for the treatment of lung infections
AU2021256086A1 (en) 2020-04-16 2022-12-15 Abionyx Pharma Sa Methods for treating acute conditions using lipid binding protein- based complexes
WO2022069942A2 (en) 2020-10-01 2022-04-07 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
WO2022076324A1 (en) * 2020-10-05 2022-04-14 Northwestern University Targeted ph sensitive liposomes
WO2022219413A1 (en) 2021-04-15 2022-10-20 Abionyx Pharma Sa Use of lipid binding protein-based complexes in organ preservation solutions
WO2023194797A1 (en) 2022-04-06 2023-10-12 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
KR20240171131A (ko) 2022-04-06 2024-12-06 아비오닉스 파마 에스에이 지질 결합 단백질-기반 복합체를 사용하여 백혈구증가증, 내피 기능장애 및 심장염을 치료하는 방법
JP2025519606A (ja) 2022-06-10 2025-06-26 アビオニクス ファーマ エスエー 脂質結合タンパク質に基づく複合体を使用して急性状態を処置するための方法
IL317448A (en) 2022-06-10 2025-02-01 Abionyx Pharma Sa Methods for treating hyperinflammatory conditions using complexes based on lipid-binding proteins
CN121219001A (zh) 2023-01-13 2025-12-26 阿比奥尼克斯制药公司 脂质结合蛋白分子疗法
WO2025093929A1 (en) 2023-10-31 2025-05-08 Abionyx Pharma Sa Lipid binding protein molecule therapy
WO2026008645A1 (en) 2024-07-02 2026-01-08 Institut National de la Santé et de la Recherche Médicale Aerosolization of apolipoprotein a1 nanoparticles enriched with alpha-1-antitrypsin for the treatment of pulmonary emphysema in patients suffering from alpha-1 antitrypsin deficiency

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19547648A1 (de) * 1995-12-20 1997-06-26 Hoechst Ag Zubereitung, enthaltend High Density Lipoproteine und Crotonsäureamidderivate
EP1212065A4 (de) * 1999-07-08 2004-02-11 Tularik Inc Zusammenstellungen und methoden zur erhöhung des hdl cholesterolspiegels
GB9919713D0 (en) * 1999-08-19 1999-10-20 Queen Mary & Westfield College New medical use of high density lipoprotein
AUPQ429399A0 (en) 1999-11-26 1999-12-23 Heart Research Institute, The Oxidized apolipoproteins and methods of use

Also Published As

Publication number Publication date
WO2003018047A2 (en) 2003-03-06
ZA200401360B (en) 2005-08-31
EP1425031A2 (de) 2004-06-09
EP1425031B1 (de) 2008-05-28
US20040266660A1 (en) 2004-12-30
JP2005501110A (ja) 2005-01-13
DE60226881D1 (de) 2008-07-10
WO2003018047A3 (en) 2004-01-29
JP4284177B2 (ja) 2009-06-24
ES2304452T3 (es) 2008-10-16
EP1425031B8 (de) 2008-09-03
CA2457840A1 (en) 2003-03-06
HK1064304A1 (en) 2005-01-28
US20080108550A1 (en) 2008-05-08
CA2457840C (en) 2011-10-11
US7491693B2 (en) 2009-02-17
AU2002340825B2 (en) 2007-07-05

Similar Documents

Publication Publication Date Title
ATE396736T1 (de) High-density -lipoprotein zur behandlung von schlaganfällen und ischämiezuständen
EA201001081A1 (ru) Соединения тетрациклина, фармацевтическая композиция и способ лечения чувствительного к тетрациклину состояния у субъекта
DK1411932T3 (da) Kombinationsterapi med substituerede oxazolidinoner
DE60319066D1 (de) 1,4-disubstituierte benzokondensierte cycloalkyl-harnstoffverbindungen zur behandlung von zytokinvermittelten erkrankungen
ATE477816T1 (de) Botulinum toxin zur behandlung von akuten verletzungen der skelettmuskeln
MY147643A (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder
GEP20053660B (en) Novel Tyrosine Kinase Inhibitors
ATE504294T1 (de) Nichtnukleosidische reverse-transkriptase-hemmer
ATE301995T1 (de) Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen
DK0665749T3 (da) Sammensætning til behandling af Parkinsons sygdom
ATE327250T1 (de) Kristallstruktur von ribosomen und proteinsynthese-inhibitoren
ATE400280T1 (de) Zusammensetzung zur verabreichung von eisen für die behandlung des unruhigen beinsyndroms
DE602004021847D1 (de) Verfahren zur prävention und behandlung von diabetes mit neurturin
ATE293976T1 (de) Verbindungen enthaltend s-tofisopam sowie verwendung dieser verbindungen zur herstellung eines medikamentes zur behandlung oder prophylaxe von krämpfen und anfällen
NO20025405D0 (no) Modulatorer for TNF-alfa-signalisering
DE602005016993D1 (de) Benzothiazolium Verbindungen zur Verwendung in Methoden zur Hemmung der NO Produktion und von TNF alpha und zur Behandlung von Coronavirus Infektionen
ATE321045T1 (de) Methoden und zusammensetzungen zur behandlung von schmerzen
EP4247800C0 (de) N-substituierte 4-(1,3-aryloxazolo-2-yl)phenyl-verbindungen zur behandlung und prophylaxe von hepatitis-b-virusinfektionen
ATE453386T1 (de) Polyamin-verbindungen zur behandlung von chemokin-rezeptor-vermittelten krankheiten
ATE420852T1 (de) Verfahren und zusammensetzungen zur behandlung oder prävention von bakteriellen infektionen
EA200301299A1 (ru) Применение ингибиторов il-18 для лечения и предотвращения повреждений цнс
DE60209886D1 (de) Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen
ATE418973T1 (de) Spirocyclopropyl-amide und -säuren und ihre therapeutischen anwendungen
DE60200531D1 (de) Mikroemulsionen zur transdermalen Verabreichung von Apomorphin für die Behandlung von Morbus Parkinson
DE60100431D1 (de) Arzneistoffkombination zur behandlung von kopfschmerzen mit mirtazapine und paracetamol oder nicht-steroiden entzündungshemmenden mitteln

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1425031

Country of ref document: EP